Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EBT (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed EBT for 10 consecutive years, with -$121.7 million as the latest value for Q4 2025.

  • Quarterly EBT fell 128.29% to -$121.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$565.0 million through Dec 2025, down 14025.0% year-over-year, with the annual reading at -$565.0 million for FY2025, 14025.0% down from the prior year.
  • EBT for Q4 2025 was -$121.7 million at Ultragenyx Pharmaceutical, up from -$179.5 million in the prior quarter.
  • The five-year high for EBT was $481.6 million in Q4 2023, with the low at -$238.8 million in Q3 2022.
  • Average EBT over 5 years is -$86.4 million, with a median of -$142.8 million recorded in 2021.
  • The sharpest move saw EBT crashed 574.02% in 2021, then surged 410.75% in 2023.
  • Over 5 years, EBT stood at -$124.8 million in 2021, then fell by 24.2% to -$155.0 million in 2022, then soared by 410.75% to $481.6 million in 2023, then dropped by 10.67% to $430.2 million in 2024, then plummeted by 128.29% to -$121.7 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$121.7 million, -$179.5 million, and -$114.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.